Alopecia Areata Registry (NAAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00069589
Recruitment Status : Active, not recruiting
First Posted : September 30, 2003
Last Update Posted : February 19, 2018
National Alopecia Areata Foundation
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

September 29, 2003
September 30, 2003
February 19, 2018
November 2001
November 2099   (Final data collection date for primary outcome measure)
Alopecia Areata Registry [ Time Frame: Registration on-going ]
Database registration of participants via collection of participant epidemiology data.
Not Provided
Complete list of historical versions of study NCT00069589 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Alopecia Areata Registry
Alopecia Areata Registry and Immunogenetic Mechanisms
Alopecia areata is the loss of hair in patches that can proceed to loss of all hair (alopecia totalis or universalis). The purpose of the registry is to collect patient information and blood samples from people with alopecia areata.

Alopecia areata is a condition in which hair is lost either from part of the scalp, all of the scalp, or the entire body, and it affects 1% to 2% of the population. It is thought to be an autoimmune disease and in some cases the disease is hereditary. The Alopecia Areata Registry will collect information and blood samples from clinically well-characterized patients with these three forms of alopecia areata: alopecia partialis (patchy loss of the scalp hair), alopecia totalis (total loss of all scalp hair), and alopecia universalis (complete loss of all hair everywhere on the body). This will be a collection of patients in multi-generational families, twins, single patients with patchy, persistent transient alopecia areata or long-standing alopecia totalis/universalis and with controls (persons unaffected and not related to alopecia patients). Information from these patients will be used to search the human genome for disease-associated loci and/or genes. Researchers interested in doing pathophysiology or treatment studies of this disease will also be able to contact patients having the appropriate form of the disease for the studies in question.

Patients who have been diagnosed with alopecia areata by a dermatologist will be eligible for the registry. Patients will fill out an information form online ( Patients who have a family history or specific types of alopecia will be invited to participate in a more detailed questionnaire and physical exam and have blood samples drawn.

Observational Model: Case-Control
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
DNA will be analyzed to learn the link between gene markers of traites of alopecia areata. Sera will be used to analyse cytokins. Lymphocytes will be used for the creation of B-cell lines.
Probability Sample

Patients with alopecia areata (AA), both children and adults, who have been diagnosed by a physician with alopecia universalis, alopecia totalis, patchy persistent AA, or transient mild AA. Family members (related by blood) of these patients, preferably sib-pairs plus parents and multiplex families(persons with at least three family members with AA or alopecia universalis and alopecia totalis).

Also, healthy individuals who are unaffected, non-blood related individuals and do not live in the same household with alopecia areata patient are needed as controls.

  • Alopecia Areata
  • Alopecia Totalis
  • Alopecia Universalis
  • Autoimmune Hair Loss
  • Alopecia Partialis
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
November 2099
November 2099   (Final data collection date for primary outcome measure)

Inclusion Criteria

  • Diagnosed with alopecia areata by a dermatologist
  • United States resident

Accepts Health Volunteers: Non blood-related individuals who are unaffected with alopecia areata and do not live in the same household with alopecia areata patient.

Sexes Eligible for Study: All
Child, Adult, Senior
Contact information is only displayed when the study is recruiting subjects
United States
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Not Provided
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Alopecia Areata Foundation
Principal Investigator: Madeleine Duvic, MD M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
February 2018